Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cytek Biosciences, Inc.CTKB · Entity 5345 | CHIEF LEGAL OFFICER | May 18, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cytek Biosciences, Inc.
Report date May 18, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 150,012 |
Ending reported balance
After 2026-05-18 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-05-18 · Exercise / conversion · Acquired 2,454 · Balance 136,890 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 2 · 2026-05-18 · Tax withholding · Disposed 881 · Balance 136,009 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 3 · 2026-05-18 · Exercise / conversion · Acquired 5,156 · Balance 141,165 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 4 · 2026-05-18 · Tax withholding · Disposed 1,850 · Balance 139,315 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 5 · 2026-05-18 · Exercise / conversion · Acquired 7,250 · Balance 146,565 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 6 · 2026-05-18 · Tax withholding · Disposed 2,602 · Balance 143,963 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Row 7 · 2026-05-18 · Exercise / conversion · Acquired 9,435 · Balance 153,398 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Row 8 · 2026-05-18 · Tax withholding · Disposed 3,386 · Balance 150,012 F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,280 |
Reported balance
After 2026-05-18 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-18 · Exercise / conversion · Disposed 2,454 · Balance 12,280 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 56,728 |
Reported balance
After 2026-05-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-18 · Exercise / conversion · Disposed 5,156 · Balance 56,728 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 123,262 |
Reported balance
After 2026-05-18 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-18 · Exercise / conversion · Disposed 7,250 · Balance 123,262 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 217,018 |
Reported balance
After 2026-05-18 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-18 · Exercise / conversion · Disposed 9,435 · Balance 217,018 F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
F4: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
F5: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
F6: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 11, 2024 Filed Mar 13, 2024 22:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 4,908 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007861 · form4-03132024_100333.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,182 Underlying: Common Stock · 4,908 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,912 | $7.22 | $13,804.64 |
DisclosureSEC source: 0001415889-24-007861 · form4-03132024_100333.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,169 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on March 11, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| March 11, 2024 Filed Mar 13, 2024 22:39 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 4,908 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-007861 · form4-03132024_100333.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,081 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:44 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 123,762 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007435 · form4-03082024_110324.xml · derivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,762 Underlying: Common Stock · 123,762 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2025 and each March 10 thereafter. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 23:44 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (right to buy) · Derivative | 184,210 | $0.00 Strike: $7.07 | $0.00 |
DisclosureSEC source: 0001415889-24-007435 · form4-03082024_110324.xml · derivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,210 Underlying: Common Stock · 184,210 shares Expires 2034-03-06 F1 · derivative.exercise_date: The shares subject to the option shall vest over 4 years with 1/48 of the total shares underlying the option vesting on April 6, 2024 and each month thereafter. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004892 · form4-02222024_100233.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,458 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $8.38 | $6,586.68 |
DisclosureSEC source: 0001415889-24-004892 · form4-02222024_100233.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,173 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 20, 2024, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:37 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-004892 · form4-02222024_100233.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · CHIEF LEGAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,959 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · derivative · entry 6 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,090 Underlying: Common Stock · 3,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · derivative · entry 5 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,474 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,434 | $5.98 | $8,575.32 |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,943 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $5.98 | $4,700.28 |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,696 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2023 Filed Nov 21, 2023 22:46 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-056347 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 3,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · derivative · entry 6 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,771 Underlying: Common Stock · 3,681 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F5 · derivative.expiration_date: The shares subject to the RSU Award shall vest over four years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · derivative · entry 5 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,490 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,434 | $8.46 | $12,131.64 |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,466 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 3,681 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $8.46 | $6,649.56 |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,219 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2023 Filed Aug 22, 2023 00:14 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046828 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,005 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1,919 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · derivative · entry 6 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,452 Underlying: Common Stock · 2,454 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · derivative · entry 5 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,506 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 956 | $6.69 | $6,395.64 |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · nonDerivative · entry 4 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,070 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,454 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · nonDerivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $6.69 | $5,258.34 |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,572 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2023 Filed May 19, 2023 23:18 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-031266 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:42 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 58,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016975 · doc4.xml · derivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,906 Underlying: Common Stock · 58,906 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting each March 10, 2024 and each March 10 thereafter, until fully vested. Read SEC document |
| March 03, 2023 Filed Mar 8, 2023 00:42 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantEmployee Stock Option (Right to Buy) · Derivative | 89,031 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001209191-23-016975 · doc4.xml · derivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,031 Underlying: Common Stock · 89,031 shares Expires 2033-03-03 F1 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over four years from the vesting commencement date of March 3, 2023. The option becomes fully vested on March 3, 2027. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:40 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-012355 · doc4.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,522 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:40 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $10.97 | $8,622.42 |
DisclosureSEC source: 0001209191-23-012355 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,342 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 23:40 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-012355 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1 share acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:13 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-058472 · doc4.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,538 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:13 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $14.75 | $11,593.50 |
DisclosureSEC source: 0001209191-22-058472 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,111 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on November 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 23:13 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-058472 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:30 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-046945 · doc4.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,554 Underlying: Common Stock · 2,016 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F4 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:30 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 786 | $14.06 | $11,051.16 |
DisclosureSEC source: 0001209191-22-046945 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,881 F3 · shares: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| August 18, 2022 Filed Aug 19, 2022 23:30 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,016 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-046945 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 2,610 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan on May 31, 2022. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionRestricted Stock Units · Derivative | 2,688 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-031161 · doc4.xml · derivative · entry 3 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,570 Underlying: Common Stock · 2,688 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Tax withholdingCommon Stock | 1,047 | $9.65 | $10,103.55 |
DisclosureSEC source: 0001209191-22-031161 · doc4.xml · nonDerivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,041 F2 · shares: Represents the number of shares withheld by and surrendered to the Issuer on May 18, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. Read SEC document |
| May 18, 2022 Filed May 20, 2022 23:09 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 2,688 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-031161 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,500 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001209191-22-017206 · doc4.xml · derivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,830 Underlying: Common Stock · 10,500 shares Expires 2031-03-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on January 19, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
| March 04, 2022 Filed Mar 8, 2022 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | Exercise / conversionCommon Stock | 10,500 | $4.71 | $49,455.00 |
DisclosureSEC source: 0001209191-22-017206 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantRestricted Stock Units · Derivative | 32,258 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014988 · doc4.xml · derivative · entry 2 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,258 Underlying: Common Stock · 32,258 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. F3 · derivative.expiration_date: The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:51 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 48,671 | $0.00 Strike: $13.64 | $0.00 |
DisclosureSEC source: 0001209191-22-014988 · doc4.xml · derivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,671 Underlying: Common Stock · 48,671 shares Expires 2032-02-28 F1 · derivative.exercise_date: 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026. Read SEC document |
| July 22, 2021 Filed Jul 27, 2021 01:50 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0001209191-21-048269 · doc4.xml · derivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-07-22 F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on July 22, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years. Read SEC document |
| July 22, 2021 Filed Jul 28, 2021 01:04 UTC | Cytek Biosciences, Inc. CTKB · Entity 5345 | PurchaseCommon Stock | 1,900 | $17.00 | $32,300.00 |
DisclosureSEC source: 0001209191-21-048389 · doc4.xml · nonDerivative · entry 1 Barnett Valerie · CIK 0001873091 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · shares: Reflects shares purchased from the underwriters in the Company's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.